Immunic, Inc. announced that at its annual meeting of stockholders on June 29, 2026, shareholders approved an amendment to the company's 2019 Omnibus Equity Incentive Plan. The amendment significantly increases the number of shares available for issuance as equity-based compensation.

Key Details

  • Share Increase: The plan was amended to increase the number of authorized shares of common stock by 6,000,000.
  • Total Authorized Shares: This brings the total number of shares authorized for issuance under the plan to 8,644,887.
  • Other Meeting Outcomes: Stockholders also elected three Class III Directors (Michael Bonney, Thorvald Nagel, and Dr. Richard Rudick) and ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.